Share Name Share Symbol Market Type Share ISIN Share Description
Motif Bio LSE:MTFB London Ordinary Share GB00BVVT4H71 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.30p -0.92% 32.30p 31.90p 32.85p 32.90p 31.75p 31.75p 788,381 16:35:15
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -33.2 -14.1 - 95.82

Motif Bio Share Discussion Threads

Showing 2451 to 2473 of 2475 messages
Chat Pages: 99  98  97  96  95  94  93  92  91  90  89  88  Older
DateSubjectAuthorDiscuss
16/7/2018
15:33
snap! in for a small stake, may add when more cash available
bountyhunter
16/7/2018
15:20
I purchased my first holding here today. It looks like it could be interesting over the next 12 months. I am rubbish at timing so hopefully now is not a bad entry point. I try to look for stocks that have market moving newsflow over the next year. Hence other holdings in my "gambling" portfolio; Evgen, Angle and Synairgen. GLA.
pdt
13/7/2018
16:36
Similar comments courtesy of floviola on LSE BB...... Graham Lumsden quoted in this piece on Novartis bailing out of the AB market. Interesting read. https://www.bloomberg.com/news/articles/2018-07-13/superbugs-win-another-round-as-big-pharma-leaves-antibiotics The departure of some big drugmakers such as Novartis “hopefully is going to add pressure to find ways to correct some market failings,” said Graham Lumsden, CEO of Motif Bio Plc, whose experimental antibiotic Iclaprim is under regulatory review in the U.S. “This is where the biotechs have to pick up the slack.”
unionhall
13/7/2018
07:08
Novartis pulls out of developing antibiotics. A bigger opportunity for Motif, less competition, good news. Motif has progressed a new antibiotic through Phase 3 trials with an under-used mechanism of action, equivalence to vancomycin, etc. The FDA, and also the EMA when the company gets its act together to put in the documents, has to fast(er) track this to approval to show pharma companies that they want them to develop new antibiotics. As they say, actions speak louder than words.
gclark
12/7/2018
15:50
I thought the company was looking at using its sales force to sell other products. Does anyone have any news on that? Meanwhile a waiting game. I'm holding for positive results
richie32
09/7/2018
17:36
Bit of a pull back today, but looking at the chart its hopefully a retest of the breakout from the down trend. So hopefully will rise from here. free stock charts from uk.advfn.com
t-trader
05/7/2018
11:49
Moving up encouragingly, ? assisted by - Bipartisan bill proposes new 'pull' incentives for priority antibiotics - 29th June 2018 :- hTtps://t.co/mz6ucRm8AV
metis20
03/7/2018
07:14
RNS. No reason for resignation.
pyglet
29/6/2018
22:21
Large successive AT trades, looks like stake building Sentiment turning, buyers and voices are slowly returning here again :-)
return_of_the_apeman
29/6/2018
16:37
Yes things have picked up. Good news and a re-rating are on the cards.
encarter
29/6/2018
15:45
Nice bit of upside movement at last, along with an increase in trading volume over the last few days. Hopefully breakout of the wedge and then up to 40p.
t-trader
17/6/2018
21:00
Coming back to my same point (!) about getting documents into the regulatory authorities, now the EMA, as quickly as possible, managing the preparation very actively, completing sections concurrently etc. Why is this so important? Patents will have an expiry - for new antibiotics the patent may be extended, and given a defined time period from marketing authorisation, I'm not sure how that relates to Iclaprim Cash flow and profitability - the company needs to generate cash flow asap, to maintain business operations and to invest in the clinical trials for the new indications Competition - the market is dynamic, there are benefits of being an earlier mover rather than later mover, getting established before other new product etc. Commercial life - there is a possibility, many years into the future, that new classes of antibiotics are developed and take away sales from Iclaprim, so looking at the total product life cycle, you maximise income by starting as early as possible From a health services perspective, Iclaprim does have benefits in renal impairment patients and this will save health services money in terms of patient management, and will make it easier and safer for patients The FDA/EMA were set up to ensure that medications were useful (efficacious) and safe (as low side effects as possible). They look at the risk/benefit of the medicine. In the case of Iclaprim, there are two clear advantages, firstly, that it has already gone before the FDA many years ago so it is already known and there will be information already filed, if that can be used; and secondly, it is seeking equivalence against standard of care/vancomycin, which I consider is strongly proven in the clinical trial. So I don't see how Iclaprim can be rejected on a risk/benefit analysis when vancomycin is the standard of care, and that presumably must have an acceptable risk/benefit. The only possible uncertainty for me would be that people are involved, sometimes with agendas, but I can't believe such people could be able to stop authorisation. For me 95% certainty of approval, as something unforeseen could always happen I suppose to account for the other 5%. But even then it would only be a delay in my view rather than a refusal.
gclark
16/6/2018
18:44
I guess you are right Small crow, they cannot get through a bill to make upskirting illegal which the whole world knows is correct apart from porn addicts and a tory pratt in the house of commons!
bowles22
16/6/2018
10:33
thechurch333, You need to find a bloke called Dave, but I have feeling he might find you.
small crow
16/6/2018
08:24
IMM How do these people keep getting a role - Alizyme was a complete disaster, I would not go anywhere near a company with this guy involved - clueless at best,IMO of course Tim McCarthy FCCA, MBA Non-Executive Chairman Mr McCarthy has a 35 year international business career in high growth biotech, healthcare and technology companies. He is currently Chairman and Non-Executive Director for a number of biotech and healthcare related companies, including Incanthera and Sygnis AG. Mr McCarthy is also the former Chief Executive Officer and Finance Director of a number UK listed public and private companies, including Alizyme plc and Peptide Therapeutics Group plc, and has a core understanding of AIM and its regulatory processes. Co-founding a number of healthcare and biotechnology companies, Mr McCarthy has helped raise substantial amounts of equity capital and also advised and worked at Board level for a diverse range of companies internationally, in areas such as business strategy, mergers & acquisitions, due diligence and lice
bowles22
15/6/2018
10:58
Am new to this stock. Don't normally invest in this sector, but this cropped up on my radar screen and it looked interesting. Thanks for a very informative and helpful BB. I'm hoping somebody may be able to answer a couple of questions for me. Firstly, there seems to be a strong consensus that the FDA will approve. I note that some brokers have ascribed a 90% chance of success. What are the most likely reasons why the FDA will NOT approve? Is there anything in any of the trial data that causes any concern? Is it possible there could be technical failings with the submission? etc. etc Secondly, what are the owners of the existing rival antibiotics saying about Iclaprim? Are they being dismissive of its potential or are there signs they are worried? Have they commented on any of the the trial results at all? Thanks
thechurch333
15/6/2018
09:36
Interesting posts thank you. gersemi I actually already have a substantial holding here however slightly underwater for the time being though I wont accumulate anymore until FDA approval. I believe this will happen and the medical world is crying out for new antibiotic treatments so it would be well received. gclark: The priority has been FDA submission completion and that's now done I suspect attention is now being given for EMA and whilst not being a total 'cut and paste' most of the information is already in place to facilitate completion in reasonable time.
catch007
15/6/2018
08:30
Answering my own question (!), I note in the final accounts they talk about submitting to both the FDA and EMA 'during 2018'. However, I just have a feeling of a lack of urgency in getting the EMA submission completed. The US is a big, company-making market, and the EU is even bigger. There is huge overlap between the two submissions, it can't take more than a couple of months to put the EMA submission together if sufficient, appropriately qualified staff are working on it - for a lot of the requirement it is now secretarial input, taking information from the FDA submission. And really all of this should have been progressing at the same time in any case. We would like a timescale for the EMA submission Obviously good news on the NDA in ABSSSI submission to the FDA and the clock is ticking …
gclark
15/6/2018
07:25
I can't remember what has been said on the timing of the submission to the EMA? clearly all resources should be put into that without delay.
gclark
15/6/2018
05:23
C007 I do have a few here though not many, yet. I believe the time to really pile in is not yet upon us so imho now is a good time to slowly accumulate bits and bobs - Is FDA approval a fait accompli? We shall see but I believe approval is far more likely than the worst case scenario, which is the FDA refusing to approve. The next step is taking on Vancowhatsitsname and persuading the medical world to start buying Iclaprim - surely there's enough room for both? Peel Hunt does have a 102p price target on MTFB - some stuff PH in the link below posted on another site HTTP://www.standard.co.uk/business/smallcap-spotlight-nex-in-focus-as-michael-spencer-takes-stake-in-chapel-down-a3862971.html#post-1132248382 - As with most of stocks I own, patience is the key -
gersemi
15/6/2018
02:10
Exactly gclark, imo just a case of waiting now and buying any dips
return_of_the_apeman
14/6/2018
16:20
two different situations though with IMM it was all about the outcome of a clinical trial where the results were unknown, although the Chairman kept on implying the results were going to be positive, in my view unprofessionally with Motif, the results of the two large trials are known, meet the primary end-points, show better results in renal patients than other medications and the outstanding issue is whether the FDA will give it a licence, which for me is almost certain for the reasons stated before
gclark
14/6/2018
16:05
gersemi: worth another punt fella? if it gets approval could be another OXB if not its another IMM …..I have a good feeling on this one though.
catch007
Chat Pages: 99  98  97  96  95  94  93  92  91  90  89  88  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:43 V: D:20180723 02:19:38